Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04639388

Understanding of Psychotic Disorders in Children With 22q11.2DS

Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Hôpital le Vinatier · Academic / Other
Sex
All
Age
4 Years – 13 Years
Healthy volunteers
Accepted

Summary

The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome

Detailed description

22q11.2DS is one of the most common microdeletion syndromes (1 / 2000-1 / 4000 births) and one of the most robust genetic risk factors for schizophrenia (1 to 2% of cases). Reciprocally, approximately 30% of patients with 22q11.2DS will develop psychotic symptoms in adolescence or early adulthood. It is now well established that children and adults with 22q11.2DS have lower social skills than developing youth. These social dysfunctions could be partly underpinned by alterations in social cognitive processes, and could also be linked to the emergence of psychotic signs or even schizophrenia. However, to our knowledge, no study has investigated the existence of behavioral prodromal signs during the onset of psychotic signs in children with 22q11.2DS. In addition, the origin of social cognitive processes remains to this day little explored.

Conditions

Interventions

TypeNameDescription
BEHAVIORALneuropsychological testing, questionnaires and experimental tasksNeuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition

Timeline

Start date
2020-11-13
Primary completion
2026-06-30
Completion
2026-09-30
First posted
2020-11-20
Last updated
2025-07-30

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04639388. Inclusion in this directory is not an endorsement.